Mural Oncology plc (MURA)
NASDAQ: MURA · Real-Time Price · USD
2.640
-0.130 (-4.69%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Company Description
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer.
The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs.
Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Mural Oncology plc
| Country | Ireland |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 116 |
| CEO | Caroline Loew |
Contact Details
Address: 10 Earlsfort Terrace Dublin, D02 T380 Ireland | |
| Phone | 353 1 905 8020 |
| Website | muraloncology.com |
Stock Details
| Ticker Symbol | MURA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001971543 |
| ISIN Number | IE000LK2BOB4 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Caroline J. Loew Ph.D. | President, Chief Executive Officer and Director |
| Adam D. Cutler B.A. | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Dr. Vicki L. Goodman M.D. | Chief Medical Officer |
| Maiken Keson-Brookes | Chief Legal Officer |
| Justin Levine | Head of Human Resources and Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | SCHEDULE 13G | Filing |
| Apr 15, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 424B5 | Filing |
| Mar 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |